A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process

Pulmonary fibrosis (PF) is chronic and irreversible damage to the lung characterized by fibroblast activation and matrix deposition. Although recently approved novel anti‐fibrotic agents can improve the lung function and survival of patients with PF, the overall outcomes remain poor. In this study,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Cell Mol Med
Auteurs principaux: Kim, Mi‐Hyoung, Jung, Seung‐Youn, Song, Kyung‐Hee, Park, Jeong‐In, Ahn, Jiyeon, Kim, Eun‐Ho, Park, Jong Kuk, Hwang, Sang‐Gu, Woo, Hee‐Jong, Song, Jie‐Young
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933341/
https://ncbi.nlm.nih.gov/pubmed/31692229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14793
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires